<DOC>
	<DOCNO>NCT00950209</DOCNO>
	<brief_summary>Atherosclerotic cardiovascular disease ( ASCD ) first cause morbidity mortality type 2 diabetes . The typical dyslipidemia associate insulin resistance , include postprandial elevation triglyceride-rich lipoprotein ( TRLs ) excess intestinal triglyceride-rich-lipoprotein-apoB48 ( TRL-apoB48 ) , felt play important role accelerate ASCD . The investigator ' objective study determine whether acute elevation plasma insulin , secondarily plasma insulin infusion , modulate production clearance rate intestinal TRL-apoB48 type 2 diabetic patient feed state determine direct effect insulin indirect effect due decrease plasma FFA decrease plasma glucose .</brief_summary>
	<brief_title>Acute Effect Intensive Insulin Infusion Intestinal Triglyceride-rich-lipoprotein-apoB48 Metabolism Type 2 Diabetic Patients</brief_title>
	<detailed_description>Background : Atherosclerotic cardiovascular disease ( ASCD ) first cause morbidity mortality type 2 diabetes . The typical dyslipidemia associate insulin resistance , include postprandial elevation triglyceride-rich lipoprotein ( TRLs ) excess intestinal triglyceride-rich-lipoprotein-apoB48 ( TRL-apoB48 ) , felt play important role accelerate ASCD . Recently , intestinal TRL-apoB48 overproduction appear newly recognize component insulin resistance . Despite ample evidence support delayed clearance intestinal TRL-apoB48 , limited amount information literature regard factor modulate production intestinal TRL-apoB48 setting insulin resistance type 2 diabetes mellitus . Several argument suggest intestine `` passive '' organ respect lipoprotein production , organ metabolically active , receive information intestinal lumen blood able modulate synthesis lipid secretion accord substrata , insulin substance . There functional relationship intestine liver . For example , recently show acute elevation plasma free fatty acid ( FFA ) humans stimulates intestinal TRL-apoB48 hepatic TRL-apoB100 production . Aims : Our objective study determine whether acute elevation plasma insulin , secondarily plasma insulin infusion , modulate production clearance rate intestinal TRL-apoB48 type 2 diabetic patient feed state determine direct effect insuline indirect effect due decrease plasma FFA decrease plasma glucose . Patients method : This study perform 30 men type 2 diabetes 2-step protocol . We use stable isotope method ( D3-L-leucine ) study kinetic intestinal TRL-apoB48 hepatic TRL-apoB100 ( production clearance rate ) . In first step protocol , patient kinetic study TRL-apoB48 condition saline infusion measure `` basal '' production clearance rate TRL-apoB48 . In second step , type 2 diabetic patient divide 3 different pair group : one perform euglycaemic hyperinsulinic clamp maintain plasma glucose around 1g/l ; one perform euglycaemic hyperinsulinic clamp maintain plasma glucose around 1g/l , infuse Endolipide 20 % ( 12,5 ml/h ) heparin ( 250 U/h ) prevent suppressive effect insulin plasma FFA ; one perform hyperglycaemic hyperinsulinic clamp maintain plasma glucose around 2 g/l prevent decrease effect insulin plasma glucose . The research ethic board Université de la Méditerranée ( Comité de protection de personnes-Sud méditerranée I ) Afssaps ( Agence française de sécurité sanitaire de produits de santé ) approve study subject give write informed consent prior participation . General objective : Given potential atherogenicity intestinal TRL-apoB48 particle , understand factor biochemical mechanism accumulation plasma insulin resistant state may lead specific therapeutic modality reduce plasma concentration protect highly prevalent atherosclerosis associate insulin resistance type 2 diabetes .</detailed_description>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Benzocaine</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>type 2 diabetic patient accord criterion American Diabetes Association body mass index 25 40 kg/m2 Subject therapeutic care base oral antidiabetic except glitazones inhibitor alphaglucosidases Subject without cardiovascular event previous 6 month perturb disease lipid balance assessment ( dysthyroidism , pituitary disease , adrenal disease ) No anemia , coagulation disturb , creatinine clearance &gt; 60 ml/min , fast triglyceride &lt; 4g/l Hypersensitivity egg Subject severe disease associate diabete</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>type 2 diabetic patient feed state</keyword>
</DOC>